NCT07028268

A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors

A Multicenter, Randomized, Double-Blind, Positively Controlled Phase II Clinical Study Evaluating the Efficacy and Safety of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 210 (estimated)
• Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study is being conducted to evaluate the efficacy, and safety of SHR-2017 Injection in Patients with Bone Metastases from Solid Tumors. To explore the reasonable dosage of SHR-2017 Injection for Bone Metastases from Solid Tumors

Conditions

• For Prevention of Bone Events in Patients With Bone Metastases From Solid Tumors

Interventions

Type	Name	Description
DRUG	SHR-2017、Denosumab placebo	SHR-2017; high dose ；Denosumab placebo
DRUG	SHR-2017、Denosumab placebo	SHR-2017; low dose ；Denosumab placebo
DRUG	Denosumab；SHR-2017 placebo	Denosumab；SHR-2017 placebo

Timeline

• Start date: 2025-06-24
• Primary completion: 2025-12-01
• Completion: 2027-05-01
• First posted: 2025-06-19
• Last updated: 2025-12-31

Locations

1 site across 1 country: China